Kymera Investor Day Presentation Deck
●
●
●
●
●
●
Expanding the Druggable Proteome with TPD
Kymera intends to drug all target classes using targeted protein degradation
A comprehensive hit finding toolbox with key Al and machine learning inputs has
been developed to identify ligands against novel E3 and undrugged targets
Our capabilities have evolved to accurately predict human active doses and
compound properties
We have developed know-how and technologies to drug inadequately drugged
targets such as IRAK4 and MDM2, undrugged targets such as STAT3 and have
for the first time in TPD drugged targets in a tissue selective manner using our E3
ligase toolbox.
Kymera has established a new discovery unit to identify new molecular glue
degrader drugs focused on undrugged/un-ligandable high value protein targets
Multiple strategic collaborations have been established to enable MG Discovery
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
KYMERA R&D DAY - December 16th, 2021
PAGE 97View entire presentation